1 – 10 of 111
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Integrating environmental outcomes in randomised clinical trials : a call to action
- Contribution to journal › Debate/Note/Editorial
-
Mark
Reflections on the Lancet Commission on Investing in Health's Global Health 2050 report – Authors' reply
- Contribution to journal › Letter
-
Mark
Epidemiological and demographic trends and projections in global health from 1970 to 2050 : a descriptive analysis from the third Lancet Commission on Investing in Health, Global Health 2050
- Contribution to journal › Article
-
Mark
Alzheimer's disease outlook : controversies and future directions
- Contribution to journal › Scientific review
-
Mark
New landscape of the diagnosis of Alzheimer's disease
- Contribution to journal › Scientific review
-
Mark
Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation : a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST)
- Contribution to journal › Article
-
Mark
New evidence for common practices in carpal tunnel syndrome
- Contribution to journal › Debate/Note/Editorial
-
Mark
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH) : a randomised, open-label, phase 2/3 superiority trial
- Contribution to journal › Article
-
Mark
Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial
- Contribution to journal › Article
-
Mark
Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2) : a multicentre, participant-masked, registry-based, randomised controlled trial
- Contribution to journal › Article
